Condition: Type 1 Diabetes · Sponsor: NYU Langone Health
This is a prospective, interventional, cohort study, meaning that researchers will follow and observe a group of enrolled study participants over a period of time (one to two months) to gather information and record any developments of the outcomes in question. This study will recruit 125 participants with Type 1 Diabetes (T1D) to: 1. Analyze the effect of reducing the cholesterol levels in the blood on platelet function. (Platelets are small cells in the blood which help form blood clots to slow or stop bleeding and to help wounds heal 2. Analyze the effect of reducing the cholesterol levels in the blood on While Blood Cell (WBC) gene expression, (White Blood Cells are part of the body's immune system which help the body fight infection and other diseases) and 3. Analyze the effect of reducing the cholesterol levels in the blood on vascular or blood vessel function.
This description comes directly from the study's public registry record.
Ira Goldberg, MD · 646-501-0589 · Ira.Goldberg@nyulangone.org
Always discuss trial participation with your own doctor first.
| New York VA Hospital | New York, New York, United States | Recruiting |
| NYC Health + Hospitals/Bellevue | New York, New York, United States | Recruiting |
| NYU Langone Health | New York, New York, United States | Recruiting |
| Mount Sinai School of Medicine | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05641753